---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-23-000027"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:16:34.358617+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akebia delays Form 10-Q filing due to accounting errors; reaffirms 2023 revenue guidance

## Summary
- Identified accounting errors in recording Auryxia return reserves, delaying Q2 2023 Form 10-Q filing.
- Reaffirms 2023 Auryxia net product revenue guidance of $175-$180 million.
- Cash as of June 30, 2023 plus Auryxia revenues expected to fund operations through at least next twelve months.
- Expects to resubmit NDA for vadadustat for anemia due to CKD in dialysis patients by end of Q3 2023.

## SEC filing metadata
- accession: 0001517022-23-000027
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000027/0001517022-23-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000027/akba-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-23-000027
- JSON: https://secwatch.observer/filing/0001517022-23-000027.json
- Plain text: https://secwatch.observer/filing/0001517022-23-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.